Acute GVHD following allogeneic HCT is an immune-triggered process, leading to profound immune dysregulation and organ dysfunction. Despite pivotal advances, aGVHD is one of the leading causes of non-relapse mortality in patients undergoing HCT.

Placenta-derived DSCs, isolated from the fetal membrane of maternal origin, are a type of stromal cells with well-characterized immunosuppressive properties. The current study is designed to assess the safety and efficacy of 4 intravenous (IV) doses of ASC930 DSC cells in aGVHD patients.

Inclusion Criteria:

• Participants ≥ 2 months of age

• Diagnosis of aGVHD grade II-IV following allogeneic HSCT according to standard criteria (Harris, 2016).

• Diagnosis of SR-aGVHD according to Mohty (2020)

• Meet one of the following criteria:

  • Participants who are Ruxolitinib-refractory, according to Mohty (2020)
  • Participants who are not eligible for SOC therapy
  • Participants who agree to receive ASC930 as a second-line therapy

• Karnofsky/Lansky Performance Status of at least 30 at the time of study entry

• Minor participants must be capable of giving written assent as appropriate per the applicable age (per local regulatory requirements).

Exclusion Criteria:

• Diagnosis of active Hepatic Sinusoidal Obstruction Syndrome (SOS)
• Presence of an active uncontrolled infection
• Active treatment for a hyprecoagulation disorder
• Evidence of diffuse alveolar hemorrhage or other active pulmonary disease
• Evidence of encephalopathy as defined by a change in mental status since the onset of aGVHD
• Evidence of relapse of malignancy
• Receival of agents other than steroids for primary treatment of aGVHD
• Severe allergic history to cell-based products